These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23318145)

  • 1. Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III.
    Sun B; Fredrickson K; Austin S; Tolun AA; Thurberg BL; Kraus WE; Bali D; Chen YT; Kishnani PS
    Mol Genet Metab; 2013 Feb; 108(2):145-7. PubMed ID: 23318145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
    van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
    Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa.
    de Vries JM; van der Beek NA; Kroos MA; Ozkan L; van Doorn PA; Richards SM; Sung CC; Brugma JD; Zandbergen AA; van der Ploeg AT; Reuser AJ
    Mol Genet Metab; 2010 Dec; 101(4):338-45. PubMed ID: 20826098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease.
    Ashe KM; Taylor KM; Chu Q; Meyers E; Ellis A; Jingozyan V; Klinger K; Finn PF; Cooper CG; Chuang WL; Marshall J; McPherson JM; Mattaliano RJ; Cheng SH; Scheule RK; Moreland RJ
    Mol Genet Metab; 2010 Aug; 100(4):309-15. PubMed ID: 20554235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved efficacy of a next-generation ERT in murine Pompe disease.
    Xu S; Lun Y; Frascella M; Garcia A; Soska R; Nair A; Ponery AS; Schilling A; Feng J; Tuske S; Valle MCD; Martina JA; Ralston E; Gotschall R; Valenzano KJ; Puertollano R; Do HV; Raben N; Khanna R
    JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa.
    Lipinski SE; Lipinski MJ; Burnette A; Platts-Mills TA; Wilson WG
    Mol Genet Metab; 2009 Nov; 98(3):319-21. PubMed ID: 19640753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease.
    Nilsson MI; Samjoo IA; Hettinga BP; Koeberl DD; Zhang H; Hawke TJ; Nissar AA; Ali T; Brandt L; Ansari MU; Hazari H; Patel N; Amon J; Tarnopolsky MA
    Mol Genet Metab; 2012 Nov; 107(3):469-79. PubMed ID: 23041258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 24-months results in two adults with Pompe disease on enzyme replacement therapy.
    Vielhaber S; Brejova A; Debska-Vielhaber G; Kaufmann J; Feistner H; Schoenfeld MA; Awiszus F
    Clin Neurol Neurosurg; 2011 Jun; 113(5):350-7. PubMed ID: 21477922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease.
    Orlikowski D; Pellegrini N; Prigent H; Laforêt P; Carlier R; Carlier P; Eymard B; Lofaso F; Annane D
    Neuromuscul Disord; 2011 Jul; 21(7):477-82. PubMed ID: 21550241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice.
    Zhu Y; Li X; McVie-Wylie A; Jiang C; Thurberg BL; Raben N; Mattaliano RJ; Cheng SH
    Biochem J; 2005 Aug; 389(Pt 3):619-28. PubMed ID: 15839836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease.
    Hawes ML; Kennedy W; O'Callaghan MW; Thurberg BL
    Mol Genet Metab; 2007 Aug; 91(4):343-51. PubMed ID: 17572127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
    Kishnani PS; Beckemeyer AA
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease.
    Lacaná E; Yao LP; Pariser AR; Rosenberg AS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):30-9. PubMed ID: 22253234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease.
    Byrne BJ; Geberhiwot T; Barshop BA; Barohn R; Hughes D; Bratkovic D; Desnuelle C; Laforet P; Mengel E; Roberts M; Haroldsen P; Reilley K; Jayaram K; Yang K; Walsh L;
    Orphanet J Rare Dis; 2017 Aug; 12(1):144. PubMed ID: 28838325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bulbar muscle weakness and fatty lingual infiltration in glycogen storage disorder type IIIa.
    Horvath JJ; Austin SL; Jones HN; Drake EJ; Case LE; Soher BJ; Bashir MR; Kishnani PS
    Mol Genet Metab; 2012 Nov; 107(3):496-500. PubMed ID: 23062577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
    Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
    Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An adult case of glycogen storage disease type IIIa.
    Kim KO; Lee HJ; Choi JW; Eun JR; Choi JH
    Korean J Hepatol; 2008 Jun; 14(2):219-25. PubMed ID: 18617770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Experience with Anaphylaxis and Desensitization to Alglucosidase Alfa in Pompe Disease.
    Ertoy Karagol HI; Inci A; Terece SP; Kilic A; Demir F; Yapar D; Koken G; Okur I; Ezgu FS; Tumer L; Bakirtas A;
    Int Arch Allergy Immunol; 2023; 184(4):370-375. PubMed ID: 36623499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial.
    Amalfitano A; Bengur AR; Morse RP; Majure JM; Case LE; Veerling DL; Mackey J; Kishnani P; Smith W; McVie-Wylie A; Sullivan JA; Hoganson GE; Phillips JA; Schaefer GB; Charrow J; Ware RE; Bossen EH; Chen YT
    Genet Med; 2001; 3(2):132-8. PubMed ID: 11286229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alglucosidase alfa: new drug. Pompe disease: a short-term benefit.
    Prescrire Int; 2007 Dec; 16(92):240-1. PubMed ID: 18092404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.